

Antwerp, 19 August 2013, 14h30 CET

## **Gimv portfolio company Endosense acquired by St.Jude Medical**

Gimv today announced that St.Jude Medical ([www.sjm.com](http://www.sjm.com)) acquired portfolio company Endosense (Switzerland). Under the terms of the agreement St.Jude Medical has agreed a purchase price of CHF 159 million upfront for 100 percent of the outstanding equity of Endosense. The terms of the transaction also provide for an additional cash payment of up to CHF 150 million, which is contingent upon both the achievement and timing of a regulatory milestone.

Endosense ([www.endosense.com](http://www.endosense.com)) was founded in 2003 in Geneva. It is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of Contact Force measurement in catheter ablation with the development of TactiCath®, the industry's first force-sensing ablation catheter.

Gimv is shareholder of Endosense since the series B round in 2009, in which the company received over CHF 38 million from Gimv, Edmond de Rothschild Investment Partners, Neomed, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital. In 2005, the enterprise already received CHF 22.6 million in its first financing round.

Based on the upfront payment, the sale already has a positive impact of EUR 5.4 million (EUR 0.22 per share) on Gimv's last published equity value at 30 June 2013. Over the entire investment period, the shareholding's return is above Gimv's historic average. No further financial details on this transaction will be disclosed.

**Link to press release St.Jude Medical:**

<http://investors.sjm.com/phoenix.zhtml?c=73836&p=irol-newsArticle&ID=1848337&highlight>

---

## ABOUT GIMV

Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 75 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employ over 26,000 professionals.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv's home markets of the Benelux, France and Germany and can count on an extended international network of experts.

More information on Gimv can be found on [www.gimv.com](http://www.gimv.com).

---

For further information please contact:

**Frank De Leenheer**, Investor Relations & Corporate Communications Manager

T +32 3 290 22 18 – [frank.deleenheer@gimv.com](mailto:frank.deleenheer@gimv.com)

**Patrick Van Beneden**, Partner Health & Care

T +32 3 290 21 58 – [patrick.vanbeneden@gimv.com](mailto:patrick.vanbeneden@gimv.com)